The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MEKiAUTO: A phase I/II open-label study of combination therapy with the MEK inhibitor cobimetinib, Immune-checkpoint blockade with atezolizumab, and the AUTOphagy inhibitor hydroxychloroquine in KRAS-mutated advanced malignancies.
 
Alexander Raufi
No Relationships to Disclose
 
Winston Wong
No Relationships to Disclose
 
Shing Mirn Lee
Consulting or Advisory Role - PTC Therapeutics
Research Funding - AstraZeneca (Inst); Karyopharm Therapeutics (Inst); Merck (Inst)
 
Gulam Abbas Manji
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - Celgene; Exelixis; Roche/Genentech
Consulting or Advisory Role - BiolineRx; Exelixis; Ipsen; Roche/Genentech
Research Funding - BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech